文献速递肺外科

临床IA期肺癌隐匿性淋巴结阳性行肺段切除的结局

Outcomes of Patients Undergoing Segmentectomy for Occult Node-Positive Clinical Stage IA Lung Cancer.
PubMed 文献 · Ann Thorac Surg · 2024-06-10

本研究基于前瞻性机构数据库,纳入759例因cT1N0M0非小细胞肺癌行肺段切除的患者,其中27例(4%)术后病理发现淋巴结升级。

要点

  • 肺段切除后隐匿性N+发生率为4%(27/759),其中15%(4/27)为N2跳跃转移。
  • 27例隐匿性N+患者中74%(20例)接受辅助治疗,未行补救性肺叶切除。
  • 匹配后肺段切除与肺叶切除的5年累积复发率、OS及局部区域复发率均无显著差异。

核心结论

  • cT1N0M0 NSCLC患者肺段切除后隐匿性N+疾病孤立局部区域复发有限,结局与肺叶切除患者相似。
  • 肺叶切除在这些患者中可能不提供优势。

研究设计与样本

  • 从前瞻性机构数据库提取因cT1N0M0 NSCLC行肺段切除后病理N+患者的临床病理资料。
  • 采用倾向评分匹配识别可比的肺叶切除队列,评估累积复发发生率和总生存(OS)。
  • 共纳入759例患者,其中27例(4%)最终病理报告淋巴结升级。

主要发现

  • 27例隐匿性N+患者中,4例(15%)为N2站跳跃转移,20例(74%)接受辅助治疗,未行补救性肺叶切除。
  • 10例(37%)出现疾病复发:3例(11%)为孤立局部区域复发,7例(26%)为远处复发。
  • 复发患者的中位复发时间为1.8年,复发后OS为3.4年。
  • 与109例肺叶切除患者行5:1匹配后,除病理N2分期和开放手术方式外,其余变量均均衡。

临床怎么用

  • 对于cT1N0M0 NSCLC行肺段切除后病理发现隐匿性N+的患者,可考虑辅助治疗,未行补救性肺叶切除。
  • 肺叶切除可能不提供额外获益,但需结合病理N2分期和手术方式等不均衡因素个体化判断。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Results of recent clinical trials suggest that segmentectomy may be an acceptable alternative to lobectomy for selected patients with early-stage non-small cell lung cancer (NSCLC). Increased use of segmentectomy may result in a concomitant increase in occult node-positive (N+) disease on surgical pathology examination. The optimal management for such patients remains unknown. METHODS: Clinicopathologic data were abstracted from a prospective institutional database to identify patients with pathologic N+ disease after segmentectomy for cT1 N0 M0 NSCLC. Propensity score matching identified a comparable lobectomy cohort for assessment of cumulative incidence of recurrence and overall survival (OS). RESULTS: Of 759 included patients, 27 (4%) had nodal upstaging on the final pathology report. Of these 27 patients, 4 (15%) had skip metastasis to N2 stations, and 20 (74%) received adjuvant therapy; no completion lobectomies were performed. Ten patients (37%) had disease recurrence: 3 isolated locoregional (11%) and 7 distant (26%). The median time to recurrence among patients with recurrence was 1.8 years; OS after recurrence was 3.4 years. After 5:1 matching with 109 patients who underwent lobectomy, all variables were balanced between the groups, except pathologic N2 stage and open surgical approach. The 5-year cumulative incidence of recurrence was not significantly different between segmentectomy and lobectomy (42% vs 52%, respectively; Gray's P = .1). The 5-year OS (63% and 50%) and rate of locoregional recurrence (12% vs 13%) were not statistically different between the groups. CONCLUSIONS: Patients with occult N+ disease after segmentectomy for cT1 N0 M0 NSCLC had limited isolated locoregional recurrences and outcomes similar to those in patients who underwent lobectomy. Lobectomy may not provide an advantage in these patients.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Nobel TB, Tan KS, Adusumilli PS, et al. Outcomes of Patients Undergoing Segmentectomy for Occult Node-Positive Clinical Stage IA Lung Cancer. Ann Thorac Surg. 2024. PMID: 38866198. doi:10.1016/j.athoracsur.2024.05.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。